FPX News and Press, First Trust US Equity Opportunities From 05/14/22

Our macroeconomic forecasting team assesses how the war and latest survey data have altered the economic outlook, policymaking and recession risks. Global growth was dragged lower, principally by steep contractions in Russia and mainland China. Barring the initial COVID-19 outbreak, M...

Pioneer Natural Resources reported tremendous YOY growth in terms of every single financial metric. The company benefited from both higher energy prices and production than in the year-ago quarter. The company is unlikely to deliver much in the way of growth over the course of thi...

The map of the Asset Allocation Committee’s market views is a buzz of activity this quarter. Coming into 2022, we anticipated slower growth compared with the steep recovery levels of 2021 and inflation that was declining but persistent—and problematic due to its origins ...

With oil prices spiking and investors avoiding volatile names, only a few themes have worked: energy and defensive stocks. With economic growth likely to slow and earnings growth harder to come by, companies able to grow earnings should garner renewed interest. To the extent reces...

Hemoglobin Oxygen Therapeutics has filed to raise $30 million in an IPO, although the final figure may change. The firm is developing alternative technologies to blood transfusions. HOTI is still in the development stage for its oxygen-carrying technologies. For further deta...

Bausch + Lomb has filed proposed terms for a $788 million IPO. The firm develops and sells contact lens and other eyecare products worldwide. BLCO has produced rebounding revenue, strong free cash flow, and is a highly regarded brand name in the eyecare space. My outlook for p...

We believe the conflict in Ukraine may turn out to be less critical for equity markets than the upcoming turn we anticipate in the economic growth cycle. In the near term, we expect the S&P 500 Index (S&P 500) to continue to recover from its March trough. We expect the dis...

The nature of the economic cycle, originally due to the COVID pandemic, has been amplified. The ongoing lockdowns and the military conflict in Europe have prompted us to revise our inflation projections further. The dynamic shifting of corporate winners and losers is a constant an...

Rising interest rates tend to hurt growth stocks, and more specifically tech stocks due to their high price-to-earnings ratios and low dividend payments. The S&P 500 is trading at its cheapest since before the pandemic, with a current P/E ratio of about 25.6. Inflation and sup...

The risk of double-digit inflation is real, as soaring commodity and agricultural input prices could have lagging and lasting effects on food prices. Cash is a traditional alternative to U.S. Treasuries from a diversification standpoint, but soaring inflation limits its typical store ...